The use of FDG PET/CT positivity as an indication for consolidation in myeloma patients after ASCT

FDG PET/CT positive patients who obtain FDG PET/CT negativity after treatment seem to have outcomes which are comparable to those of patients who were FDG PET/CT negative at baseline.
In this MEDtalk, Fredrik H. Schjesvold, chief of the Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Norway, shares his perspective on the CONPET study.
149 FDG PET/CT positive patients were included in the treatment phase which consists of four 28-day cycles of KRd (carfilzomib, lenalidomide and dexamethasone). After the four cycles, FDG PET/CT and Euroflow for MRD were repeated for response evaluation.
Both patients with FDG PET/CT negativity and patients with FDG PET/CT positivity at baseline are followed for progression free survival and overall survival.